坂本 信二郎SHINJIRO SAKAMOTO

Last Updated :2024/04/03

所属・職名
病院（医）　助教
メールアドレス
s-sakamotohiroshima-u.ac.jp
自己紹介
様々な呼吸器疾患に精通しながら、とくに肺癌・癌免疫に関する研究を行っています

基本情報

学位

  • 博士（医学）　(広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 呼吸器内科学

研究キーワード

  • 呼吸器内科

所属学会

  • 日本内科学会
  • 日本呼吸器学会

教育活動

授業担当

  1. 2024年, 学部専門, 通年, 器官・システム病態制御学I
  2. 2024年, 学部専門, 集中, 症候診断治療学
  3. 2024年, 学部専門, 集中, 臨床実習I
  4. 2024年, 学部専門, 集中, 臨床実習II

研究活動

学術論文（★は代表的な論文）

  1. ★, HLA-A11もしくは-A33のがん患者に対するペプチドワクチンの免疫学的評価, Cancer Sci., 108巻, 4号, pp. 598-603
  2. ★, Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer, CLINICAL LUNG CANCER, 18巻, 6号, pp. E385-E394, 201711
    DOIを用いた論文検索結果へのリンク
  3. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8巻, 55号, pp. 94382-94392, 20171107
    DOIを用いた論文検索結果へのリンク
  4. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119巻, pp. 21-24, 201805
    DOIを用いた論文検索結果へのリンク
  5. ★, Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele, CANCER SCIENCE, 106巻, 10号, pp. 1257-1263, 2015
  6. ★, Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination, HUMAN VACCINES & IMMUNOTHERAPEUTICS, 11巻, 12号, pp. 2784-2789, 2015
  7. ★, Prospect and progress of personalized peptide vaccinations for advanced cancers, EXPERT OPINION ON BIOLOGICAL THERAPY, 16巻, 5号, pp. 689-698, 2016
  8. Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016
  9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site, CANCER IMMUNOLOGY IMMUNOTHERAPY, 65巻, 10号, pp. 1223-1231, 2016
  10. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer, CANCER SCIENCE, 108巻, 5号, pp. 838-845, 2017
  11. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens, INTERNATIONAL JOURNAL OF ONCOLOGY, 46巻, 1号, pp. 55-62, 2015
  12. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer, CANCER SCIENCE, 105巻, 10号, pp. 1229-1235, 2014
  13. Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination, ONCOLOGY LETTERS, 13巻, 2号, pp. 993-999, 2017
  14. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32巻, 5号, pp. 1155-1160, 2018
  15. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32巻, 5号, pp. 1155-1160, 2018
    DOIを用いた論文検索結果へのリンク
  16. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9巻, 5号, pp. 539-544, 201811
    DOIを用いた論文検索結果へのリンク
  17. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97巻, 49号, 201812
    DOIを用いた論文検索結果へのリンク
  18. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442巻, pp. 31-39, 2019
    DOIを用いた論文検索結果へのリンク
  19. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98巻, 5号, 201902
    DOIを用いた論文検索結果へのリンク
  20. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98巻, 12号, 201903
    DOIを用いた論文検索結果へのリンク
  21. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23巻, 4号, pp. 2984-2994, 201904
    DOIを用いた論文検索結果へのリンク
  22. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58巻, 7号, pp. 915-920, 2019
    DOIを用いた論文検索結果へのリンク
  23. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136巻, pp. 52-59, 20190520
    DOIを用いた論文検索結果へのリンク
  24. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152巻, pp. 44-50, 201906
    DOIを用いた論文検索結果へのリンク
  25. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57巻, 5号, pp. 451-459, 201909
    DOIを用いた論文検索結果へのリンク
  26. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8巻, 55号, pp. 94382-94392, 2017
  27. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer, CLINICAL LUNG CANCER, 18巻, 6号, pp. E385-E394, 2017
  28. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119巻, pp. 21-24, 2018
  29. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9巻, 5号, pp. 539-544, 2018
  30. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97巻, 49号, 2018
  31. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442巻, pp. 31-39, 2019
  32. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98巻, 5号, 2019
  33. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98巻, 12号, 2019
  34. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23巻, 4号, pp. 2984-2994, 2019
  35. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58巻, 7号, pp. 915-920, 2019
  36. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136巻, pp. 52-59, 2019
  37. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152巻, pp. 44-50, 2019
  38. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 2019
  39. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57巻, 5号, pp. 451-459, 2019
  40. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A11(+) or-A33(+) allele, CANCER SCIENCE, 108巻, 4号, pp. 598-603, 2017
  41. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98巻, 3号, pp. 212-220, 201909
    DOIを用いた論文検索結果へのリンク
  42. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39巻, 10号, pp. 5725-5731, 201910
    DOIを用いた論文検索結果へのリンク
  43. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58巻, 21号, pp. 3129-3132, 2019
    DOIを用いた論文検索結果へのリンク
  44. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25巻, 1号, pp. 74-81, 202001
    DOIを用いた論文検索結果へのリンク
  45. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25巻, 1号, pp. 74-81, 202001
    DOIを用いた論文検索結果へのリンク
  46. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12巻, 3号, pp. 1079-1084, 202003
    DOIを用いた論文検索結果へのリンク
  47. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25巻, 3号, pp. 275-280, 202003
    DOIを用いた論文検索結果へのリンク
  48. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients, INTERNATIONAL JOURNAL OF ONCOLOGY, 56巻, 6号, pp. 1479-1479, 202006
    DOIを用いた論文検索結果へのリンク
  49. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21巻, 1号, 20200611
    DOIを用いた論文検索結果へのリンク